Corporate News

Xenon MRI featured prominently at ATS 2025 across broad clinical spectrum
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, will be featured at the American Thoracic Society’s (ATS) 2025 Respiratory Innovation Summit (RIS), taking place May 16–17 at the Marriott Marquis in San Francisco, California. Polarean will also attend the ATS 2025 International Conference from May 18–21, continuing its active engagement with leaders across pulmonary medicine. 

Polarean’s selection as a featured company at RIS 2025 underscores the growing recognition of the company’s Xenon MRI platform as an innovative tool for both clinical imaging and pharmaceutical drug development. RIS brings together key innovators, investors, clinicians, and patient advocacy groups for cross-sector dialogue on the future of respiratory care. 

At the ATS 2025 International Conference, Xenon MRI will be featured in over 30 posters and presentations from more than 10 leading clinical sites. This robust presence reinforces the sustained momentum behind Xenon MRI as a powerful and enduring technology in pulmonary medicine. The breadth and depth of research presented this year further demonstrate its expanding role in both clinical care and clinical trials - signaling that Xenon MRI is not just innovative, but a lasting part of the respiratory care landscape. 

The presentations listed below will highlight Xenon MRI’s versatility across a wide spectrum of respiratory conditions, including asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, pulmonary arterial hypertension, radiation-induced lung injury, and post-transplant lung monitoring.

Polarean representatives will be on-site throughout RIS and the ATS International Conference to connect with clinicians, researchers, industry partners, and patient advocates. As excitement continues to build around functional lung imaging, Polarean remains at the forefront — visualizing hidden disease, personalizing treatment, and accelerating the future of respiratory medicine.

Christopher von Jako, PhD, CEO of Polarean, said: “We are honoured to return as a featured company at the Respiratory Innovation Summit. RIS and the ATS International Conference provide vital opportunities to engage with thought leaders, strengthen partnerships, and highlight the growing body of clinical evidence supporting Xenon MRI. With over 30 presentations this year, it’s clear that Xenon MRI is not only gaining traction—it’s shaping the future of functional lung imaging and respiratory care.”

See the listing below for details on the presentation title, abstract number, session time, and location.  

Enquiries:

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.

XENOVIEW IMPORTANT SAFETY INFORMATION  

Indication

XENOVIEW®, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging. 

CONTRAINDICATIONS

None. 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold. 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated. 

Adverse Reactions 

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age. 

Please see full prescribing information at www.XENOVIEW.net